RENOVARO INC (RENB)
(Real Time Quote from BATS)
$0.58 USD
-0.03 (-4.13%)
Updated Sep 18, 2024 11:40 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
RENB 0.58 -0.03(-4.13%)
Will RENB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RENB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for RENB
Independent Expert Assessment Validates RenovaroCube?s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
PersonalAIze conducted evaluation on Renovaro's RenovaroCube
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
Renovaro BioSciences to present cancer diagnostics research at ESMO Congress
RenovaroCube Announces Strategic Offering of Up to 20% Ownership